Among the 10 Antiretrovirals with the Highest Part D Spending in 2017, All Had List Price Increases Exceeding Inflation
All 10 Part D ARVs w Highest Spending Had Price Increases Above Inflation Download…
View the Latest: Medicare Part D
Filter
-
-
Almost Three-Quarters of Antiretrovirals Covered by Medicare Part D Had List Price Increases Above Inflation Between 2016 and 2017
FeatureThree-quarters of Part D ARVs Had Price Increases Above Inflation Download…
-
Most Antiretrovirals Covered by Medicare Part D (as of 2017) Are Brand-Name, Single Source Medications
FeatureMost ARVs Covered by Medicare Part D are Brand Single Source Download…
-
Quick Look: Antiretroviral Price Increases in Medicare Part D
Issue BriefDrug price concerns in the U.S., including for antiretrovirals, the mainstay of HIV treatment and, increasingly prevention, have prompted the introduction of several policy proposals. One proposal would require manufacturers to provide a rebate to the federal government if prices increase faster than inflation. We assessed list price changes for ARVs under Part D, which is required to cover all or substantially all ARVs.
-
A Small Share of People with Medicare Advantage or Stand-alone Medicare Part D Coverage Voluntarily Switch Plans During Open Enrollment
News ReleaseA new KFF analysis finds that a relatively small share of people with Medicare Advantage or stand-alone Medicare Part D prescription drug coverage voluntarily switch plans during Medicare’s open enrollment period, which runs annually from Oct. 15 to Dec. 7.
-
A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries
Issue BriefIn response to higher drug spending growth and heightened attention to drug prices, policymakers have proposed a variety of policy initiatives to lower the cost of prescription drugs in Medicare. This brief examines in detail the range of proposals offered by the Trump Administration and members of Congress for lowering the cost of prescription drugs, their known effects on the federal budget, and their potential implications for beneficiaries and other stakeholders.
-
Millions of Medicare Part D Enrollees Face Increases in Premiums and Other Costs in 2020 if They Do Not Switch Plans During Open Enrollment
News ReleaseMillions of current enrollees in stand-alone Medicare Part D prescription drug plans will face premium and other cost increases next year unless they switch to lower-cost plans during the open enrollment period that began Oct. 15 and ends on Dec. 7, a new KFF analysis finds.
-
Medicare Part D: A First Look at Prescription Drug Plans in 2020
Issue BriefThis issue brief provides an overview of the Medicare Part D prescription drug benefit plan landscape for 2020, with a focus on stand-alone drug plans, the largest segment of the Part D market. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D plans available in 2020.
-
Analysis Finds Record 3,148 Medicare Advantage Plans Will be Available in 2020
News ReleaseA record 3,148 Medicare Advantage plans will be available across the country as alternatives to traditional Medicare, a new KFF analysis finds.
-
Medicare Advantage 2020 Spotlight: First Look
Issue BriefIn 2020, more than 22 million Medicare beneficiaries (34%) are enrolled in Medicare Advantage plans, which are mainly HMOs and PPOs offered by private insurers as an alternative to the traditional Medicare program. This data note provides an overview of the Medicare Advantage plans that will be available in 2020, including the variation in the number of plans available by county and plan type. The brief also examines the insurers entering the Medicare Advantage market for the first time and also examines the insurers exiting the market.